Efficacy News and Research

RSS

UA researchers developing new treatment to delay serious consequences of venomous snakebites

Time is of the essence for treating venomous snakebites, and a product being developed by researchers at the University of Arizona College of Medicine - Tucson may extend that window for treatment.

18 Apr 2016

LOXO-101 drug shows efficacy with tumor regression in varied types of genetically defined cancer

A phase I study of the drug LOXO-101 appears to significantly reduce tumors in patients with varied types of genetically defined cancer, according to a study led by The University of Texas MD Anderson Cancer Center.

18 Apr 2016

Computer-based cognitive remediation at home can improve cognitive symptoms in MS patients

Cognitive impairment is one of the core symptoms of multiple sclerosis (MS) -- and one of its most troubling concerns for many people with the condition. Now, a new study from NYU Langone Medical Center may provide hope for symptomatic relief for some of the cognitive issues associated with the neurological disease.

18 Apr 2016

Genetic modification of common virus gives extra weapon to kill cancer cells

A common flu virus could be used to overcome patients' resistance to certain cancer drugs -- and improve how those drugs kill cancer cells, according to new research from Queen Mary University of London.

16 Apr 2016

Investigators find tacrolimus to be very effective in reducing ocular symptoms of GVHD

Researchers from Massachusetts Eye and Ear/Harvard Medical School have conducted a clinical trial comparing the safety and efficacy of topical tacrolimus, an immunosuppressive therapy, and topical methylprednisolone, a steroid medication, in patients with ocular graft-versus-host-disease (GVHD) -- a complication associated with allogeneic bone marrow transplants in which the transplanted immune system's cells attack certain parts of the recipient's body, including the cornea and ocular surface.

16 Apr 2016

Slow-wave sleep may promote consolidation of recent memories

Research strongly suggests that sleep, which constitutes about a third of our lives, is crucial for learning and forming long-term memories. But exactly how such memory is formed is not well understood and remains, despite considerable research, a central question of inquiry in neuroscience.

16 Apr 2016

M10 peptide could help protect systemic sclerosis patients against fibrotic damage

The results of preclinical studies by investigators at the Medical University of South Carolina (MUSC) reported in the April 2016 issue of Translational Research suggest that the M10 peptide could help protect against fibrotic damage in patients with systemic sclerosis, particularly in those who develop interstitial lung diseases (ILD), its deadliest complication.

15 Apr 2016

AstraZeneca reports new Phase I extended follow-up data on osimertinib in NSCLC patients at ELCC 2016

AstraZeneca today reported new Phase I extended follow-up data on osimertinib in both first- and second-line treatment of patients with non-small cell lung cancer (NSCLC), at the European Lung Cancer Conference (ELCC) 2016. Late-breaker presentations reinforced the efficacy and safety profile for osimertinib previously seen in the AURA clinical trials programme.

15 Apr 2016

Researchers develop novel method to store microfluidic devices for CD4 T cell testing

Providing vital health care services to people in developing countries without reliable electricity, refrigeration and state-of-the-art medical equipment poses a number of challenges. Inspired by pregnancy tests, researchers from Florida Atlantic University, Stanford University, and Baskent University in Turkey, have developed a novel method to store microfluidic devices for CD4 T cell testing in extreme weather conditions for up to six months without refrigeration.

14 Apr 2016

Epigenomics receives FDA approval for Epi proColon®

Epigenomics AG, the German-American cancer molecular diagnostics company, has announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s lead product, Epi proColon®, the first and only FDA-approved blood-based colorectal cancer screening test.

14 Apr 2016

Innate Immunotherapeutics announces clinical trial fully enrolled and receives strong interest from potential Pharma partners

Innate Immunotherapeutics Limited has closed enrolment into the Company's Phase 2B placebo controlled efficacy trial of MIS416 in patients with secondary progressive multiple sclerosis (SPMS). The study has exceeded the original recruitment target of 90 subjects with the successful enrolment this week of the 93rd patient.

14 Apr 2016

TDF, entecavir duo 'highly effective' for difficult-to-treat chronic HBV

The combination of tenofovir disoproxil fumarate and entecavir induces a high rate of viral suppression in patients with chronic hepatitis B virus infection who have failed multiple nucleos(t)ide analogue regimens, phase IIIb results indicate.

13 Apr 2016

UC San Diego receives NIH grant to establish interdisciplinary center to combat antibiotic resistance

Researchers at University of California, San Diego School of Medicine have received a five-year, $9.5-million award from the National Institute of Allergy and Infectious Diseases at the National Institutes of Health to establish an interdisciplinary center to define the systems biology of antibiotic resistance. The program will be led by Bernhard Palsson, PhD, Distinguished Professor of Bioengineering and Pediatrics, and Victor Nizet, MD, professor of pediatrics and pharmacy.

13 Apr 2016

Novel biochemical method can extend lifetime of implantable medical devices

Blood-contacting implantable medical devices, such as stents, heart valves, ventricular assist devices, and extracorporeal support systems, as well as vascular grafts and access catheters, are used worldwide to improve patients' lives. However, these devices are prone to failure due to the body's responses at the blood-material interface; clots can form and inflammatory reactions can prevent the device from performing as indicated. Currently, when this occurs, the only solution is to replace the device.

13 Apr 2016

Studies offer alternative conclusions on efficacy of DAAs for HIV and HCV co-infected patients

Two separate studies presented today at The International Liver Congress 2016 in Barcelona, Spain have offered alternative conclusions regarding the efficacy of direct-acting antivirals (DAAs) among patients co-infected with HIV and Hepatitis C virus (HCV).

13 Apr 2016

RedHill Biopharma initiates phase II study of BEKINDA for irritable bowel syndrome

RedHill Biopharma Ltd. (NASDAQ; RDHL) (TASE: RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that it has initiated a randomized, double-blind, 2-arm parallel group Phase II clinical study in the U.S. evaluating the safety and efficacy of BEKINDA™ 12 mg in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).

13 Apr 2016

Pooled analysis from seven clinical studies demonstrates consistent efficacy for ceftazidime-avibactam in the treatment of multi-drug resistant gram-negative bacteria

AstraZeneca has presented positive data demonstrating the efficacy of the investigational antibiotic, ceftazidime-avibactam (CAZ-AVI), in treating patients with ceftazidime-resistant Gram-negative infections, which are increasingly resistant to most available antibiotics, often precipitating the need for clinicians to reach for agents previously reserved for last-line use.

12 Apr 2016

Innovative HIV vaccine candidate generates protection against repeated AIDS virus exposures

Mymetics Corporation, a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases across mucosal membranes, announced today that its innovative HIV vaccine candidate has shown to generate significant protection in groups of twelve female monkeys against repeated AIDS virus exposures during part of the preclinical study.

11 Apr 2016

Novel nanoparticle drug delivery system for enhanced tumor penetration of cancer drugs

For more than a decade, biomedical researchers have been looking for better ways to deliver cancer-killing medication directly to tumors in the body. Tiny capsules, called nanoparticles, are now being used to transport chemotherapy medicine through the bloodstream, to the doorstep of cancerous tumors.

11 Apr 2016

Long-term medication use reduces risk of relapse and improves symptoms in BDD patients

People with Body Dysmorphic Disorder (BDD) fare better and are less likely to relapse when treated with medication on a long-term basis, according to researchers at Rhode Island Hospital and Massachusetts General Hospital.

11 Apr 2016

Efficacy News and Research

UA researchers developing new treatment to delay serious consequences of venomous snakebites

LOXO-101 drug shows efficacy with tumor regression in varied types of genetically defined cancer

Computer-based cognitive remediation at home can improve cognitive symptoms in MS patients

Genetic modification of common virus gives extra weapon to kill cancer cells

Investigators find tacrolimus to be very effective in reducing ocular symptoms of GVHD

Slow-wave sleep may promote consolidation of recent memories

M10 peptide could help protect systemic sclerosis patients against fibrotic damage

AstraZeneca reports new Phase I extended follow-up data on osimertinib in NSCLC patients at ELCC 2016

Researchers develop novel method to store microfluidic devices for CD4 T cell testing

Epigenomics receives FDA approval for Epi proColon®

Innate Immunotherapeutics announces clinical trial fully enrolled and receives strong interest from potential Pharma partners

TDF, entecavir duo 'highly effective' for difficult-to-treat chronic HBV

UC San Diego receives NIH grant to establish interdisciplinary center to combat antibiotic resistance

Novel biochemical method can extend lifetime of implantable medical devices

Studies offer alternative conclusions on efficacy of DAAs for HIV and HCV co-infected patients

RedHill Biopharma initiates phase II study of BEKINDA for irritable bowel syndrome

Pooled analysis from seven clinical studies demonstrates consistent efficacy for ceftazidime-avibactam in the treatment of multi-drug resistant gram-negative bacteria

Innovative HIV vaccine candidate generates protection against repeated AIDS virus exposures

Novel nanoparticle drug delivery system for enhanced tumor penetration of cancer drugs

Long-term medication use reduces risk of relapse and improves symptoms in BDD patients

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News